President Trump plans to remove FDA Commissioner Marty Makary from his post, marking an abrupt end to a tumultuous tenure at the agency, according to multiple reports.
The decision reflects mounting friction between Makary and Trump's inner circle over several contentious regulatory matters. Despite Makary's early alignment with the administration's Make America Healthy Again movement, disagreements over specific policy decisions have strained the relationship beyond repair.
The flashpoints include Makary's positions on vaping regulation, access to the abortion pill, and his rejection of certain new drug approvals. These stances put him at odds with key figures in the Trump administration who had different expectations for how the FDA would operate under new leadership.
Makary, a physician and Johns Hopkins surgeon, came to the FDA role with a public health background and had been viewed as an ally of the broader health agenda Trump campaigned on. However, the gap between campaign rhetoric and the day-to-day enforcement decisions required at the FDA proved wider than anticipated.
The timing of the firing comes as the administration continues reshaping federal agencies to align with Trump's second-term priorities. The FDA, which oversees drugs, medical devices, and food safety, holds enormous influence over American health policy, making the commissioner role one of the most powerful positions in the regulatory state.
It remains unclear who Trump intends to nominate as Makary's replacement, though the administration is expected to seek a candidate with stronger alignment on the issues that led to this split.
Author Sarah Mitchell: "Makary's ouster shows that ideological compatibility isn't enough at this level, the FDA still answers to Trump's vision of how regulations should work."
Comments